nVerses Capital’s Cogent Biosciences COGT Stock Holding History

nVerses Capital’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-7,000	Closed	-$75.6K	–	188
2024 Q3	$75.6K	Buy	+7,000	New	+$68.2K	0.03%	533

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

nVerses Capital's COGT Position: Q4 2024 in Review

nVerses Capital sold out of Cogent Biosciences (COGT) in Q4 2024, closing a stake of 7,000 shares — an estimated $75.6K sold.

nVerses Capital first reported a position in COGT in Q3 2024 and held it in 1 quarter. The position peaked at $75.6K in Q3 2024. 176 funds tracked by Wall St. Rank hold COGT as of Q4 2024.

nVerses Capital reported no remaining Cogent Biosciences position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 7,000 Cogent Biosciences shares in Q4 2024, an estimated $75.6K.
nVerses Capital first reported a position in Cogent Biosciences in Q3 2024 and held it in 1 quarter.
nVerses Capital's Cogent Biosciences position peaked at $75.6K in Q3 2024.
176 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.